Peptide · Fact sheet

Thymosin alpha-1

Also known as Tα1 · thymalfasin · Zadaxin

Thymosin alpha-1 is a 28-amino-acid immune-signaling peptide studied in infections, sepsis, liver disease, and cancer-support settings. It is not FDA approved to prevent or treat infection, 'boost immunity,' treat cancer, or for any other U.S. use.

Not FDA approvedModerate human evidence

What is Thymosin alpha-1?

Thymosin alpha-1 is a synthetic version of a peptide derived from prothymosin alpha and studied as an immune modulator.

It is distinct from thymosin beta-4 and from the TB-500 fragment; the shared 'thymosin' name does not make their biology or evidence interchangeable.

Benefits & claims

Trials have explored chronic hepatitis, sepsis, immune dysfunction, respiratory infections, and combinations with cancer treatment.

Broad 'immune boost' marketing flattens condition-specific and sometimes conflicting trial findings into a claim the evidence cannot support.

What the evidence supports

  • Some trials and meta-analyses report signals in selected sepsis or hepatitis outcomes.
  • Other randomized studies found no significant benefit on key clinical endpoints, so results cannot support a universal immune claim.
Research areas
  • Sepsis and critical-illness immune dysfunction
  • Chronic hepatitis B and C
  • Respiratory and other infections
  • Immune support alongside cancer treatment
  • Condition-specific immune modulation
  • Adjunctive research in infections, liver disease, and cancer care

Dosage & frequency

No established human regimen

Thymosin alpha-1 has human disease-specific trials but no FDA-approved general immune-boosting or longevity regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • An adjunctive protocol for a particular infection or disease cannot establish a universal immune-support schedule.

Interactions & precautions

  • Disease-specific adjunct trials do not establish a universal interaction profile with immunosuppressants or other immune-active treatments.

What is still unresolved

  • Which population, route and schedule has a reproducible favorable benefit–risk balance?

Side effects & risks

  • FDA identifies potential immune reactions, peptide impurities, active-ingredient characterization problems, and inadequate safety information for compounded products.
  • Immune modulation can have condition-specific tradeoffs, especially in severe illness or alongside other treatments.
  • Unapproved products introduce quality, purity, sterility, strength, and labeling uncertainty.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Moderate human evidence

Multiple human trials exist, including randomized studies in hepatitis and sepsis, but results vary by condition and design. The evidence does not support a general immune-enhancement claim or an FDA-approved U.S. use.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Positive account · personal report

More capacity for work and daily activity

An author with self-described post-COVID ME/CFS reported returning to full-time work, gardening and walks after several months, while neurological symptoms remained.

Amount, frequency, route and duration could not be confirmed for this account.

Prior hyperbaric oxygen, acupuncture, pacing and the fluctuating illness complicate attribution. Diagnosis and recovery were not verified.

Read the original account
Negative account · personal report

Fatigue, throat symptoms and gas

An author described feeling sluggish and unwell, with throat and lymph-node discomfort and unusually frequent gas during the first four days.

Reported use in this account

Product
Product labeled thymosin alpha-1
Amount
Not specified clearly
Frequency
Daily
Route
Not specified clearly
Duration
Four days at the time of the post

The author already had fatigue and self-reported Epstein–Barr-related illness. No follow-up established the cause or duration.

Read the original account

Approval status

Thymosin alpha-1 has no FDA-approved product or indication. FDA has specifically stated that it is not approved to treat or prevent COVID-19 or any other condition and identifies compounded-product evidence and quality concerns.

No U.S. approval despite human research

Thymosin alpha-1 has human studies and non-U.S. product history, but FDA states it has no approved U.S. indication and identifies compounded-product concerns.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Which specific conditions and patient subgroups, if any, have a reproducible clinical benefit
  • Long-term and uncommon harms
  • How it compares with current standard treatments
  • Whether findings from one formulation, country, or clinical setting transfer to another

Summary

Thymosin alpha-1 has more human research than many experimental peptides, but the evidence is condition-specific and mixed. It should not be described as a general immune booster or an FDA-approved U.S. therapy.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

  2. fdaFDA annual report: unapproved thymosin alpha-1 claims

    FDA statement that thymosin alpha-1 is not approved to treat or prevent COVID-19 or any other condition.

  3. pubmedETASS randomized sepsis trial

    Multicenter randomized study in severe sepsis with important setting and design limits.

  4. pubmedPhase 3 chronic hepatitis B trial

    Randomized placebo-controlled trial whose primary response difference was not statistically significant.

  5. pubmedRandomized study in HBV-related cirrhosis

    Large randomized study finding no significant difference in the composite clinical endpoint.

How we assess sources · Suggest a correction